Hydroxytyrosol (Synonyms: DOPET; 3,4-Dihydroxyphenethyl alcohol; 3-Hydroxytyrosol)

Name: Hydroxytyrosol
Brand: MedChemExpress
SKU: HY-N0570
Rating: 5.0 (6 reviews)

Cat. No.: HY-N0570 Purity: 98.24%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Hydroxytyrosol (DOPET) is a phenol found in the olive oil. Hydroxytyrosol can alleviate oxidative stress and improve mitochondrial function, thereby exerting neuroprotective effects. Hydroxytyrosol can induce cancer cells apoptosis via inducing ROS production. Hydroxytyrosol shows antibacterial and antiviral effect. Hydroxytyrosol can be used for the researches of cancer, infection, inflammation, immunology, metabolic, neurological and cardiovascular disease, such as colon cancer, diabetes, Alzheimer's Disease and atherosclerosis.

For research use only. We do not sell to patients.

Hydroxytyrosol Chemical Structure

CAS No. : 10597-60-1

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid or liquid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid or liquid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Other Forms of Hydroxytyrosol:

6 Publications Citing Use of MCE Hydroxytyrosol

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Microbial Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
DG-75	IC₅₀	58 μg/mL Compound: 2, HT	Cytotoxicity against human DG75 cells after 48 hrs by MTT assay Cytotoxicity against human DG75 cells after 48 hrs by MTT assay	[PMID: 18823782]
HeLa	IC₅₀	70 μg/mL Compound: 2, HT	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 18823782]
MDCK	CC₅₀	> 172.11 μM Compound: 4b	Cytotoxicity against MDCK cells after 72 hrs by MTT assay Cytotoxicity against MDCK cells after 72 hrs by MTT assay	[PMID: 24803363]
MDCK	IC₅₀	17.53 μM Compound: 4b	Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 2 to 3 days by crystal violet staining-based plaque reduction assay Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 2 to 3 days by crystal violet staining-based plaque reduction assay	[PMID: 24803363]
MRC5	IC₅₀	> 50 μM Compound: 2; HT	Cytotoxicity against human MRC5 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 27155468]
Platelet	IC₅₀	27 μM Compound: Htyr; Hydroxytyrosol	Inhibition of ADP-induced platelet aggregation in human platelet rich plasma preincubated for 10 mins Inhibition of ADP-induced platelet aggregation in human platelet rich plasma preincubated for 10 mins	[PMID: 26225717]
Platelet	IC₅₀	67 μM Compound: Htyr; Hydroxytyrosol	Inhibition of collagen-induced platelet aggregation in human platelet rich plasma preincubated for 10 mins Inhibition of collagen-induced platelet aggregation in human platelet rich plasma preincubated for 10 mins	[PMID: 26225717]
SK-BR-3	IC₅₀	201.1 μM Compound: Hydroxytyrosol	Antiproliferative activity against human SKBR3 cells after 72 hrs by MTT reduction assay Antiproliferative activity against human SKBR3 cells after 72 hrs by MTT reduction assay	[PMID: 28551177]

In Vitro

Hydroxytyrosol inhibits cells proliferation and inhibits LPS (HY-D1056)-induced TNF-a, IL-1b, IL-6 and IL-17 secretion in splenocytes and peritoneal macrophages from SLE mice^[4].
Hydroxytyrosol (100 μg/mL) inhibits Staphylococcus aureus with the highest Zone of inhibition of 30 mm, and Staphylococcus epidermidis of 25 mm^[5].
Hydroxytyrosol shows MIC of 3.125 μg/mL against Staphylococcus aureus^[5].
Hydroxytyrosol (50-200 μg/mL, 24-48 h) inhibits proliferation, decreases mitochondrial membrane potential and induces apoptosis and ROS production in DLD1 cells^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[7]

Cell Line:	DLD1 cells
Concentration:	50, 100 and 200 μg/mL
Incubation Time:
Result:	Inhibited the growth of DLD1 cells in a concentration and time-dependent manner.

In Vivo

Hydroxytyrosol (20-40 mg/kg, i.g., daily for 10 days) inhibits inflammation and increases survival rate in LPS (HY-D1056)-mediated septic mice^[1].
Hydroxytyrosol (10 mg/kg, p.o., daily for 10 weeks) increases atherosclerotic lesion in Apo E deficient mice with low cholesterol-diet^[2].
Hydroxytyrosol (5 mg/kg, i.g., daily for 6 months) improves cognitive function in APP/PS1 mice^[3].
Hydroxytyrosol (0.4 mg, p.o., daily for 6 months) prevents Pristine (HY-N7819)-induced systemic lupus erythematous (SLE) in mice^[4].
Hydroxytyrosol (1-10 mg/kg, p.o., daily for 2 months) shows neuroprotective effect in diabetic rats^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	LPS (HY-D1056) )-mediated septic mice models^[1]
Dosage:	20 and 40 mg/kg
Administration:	Orally gavage, daily for 10 days
Result:	Increased survival rate. Inhibited the incidence of oxidative damage in splenic tissue. Decreased total leukocytes count, C-reactive protein, monocyte chemoattractant protein-1, and myeloperoxidase levels. Suppressed the production levels of tumor necrosis factor-a, interleukin-1b, and interleukin-6. Increased mRNA expression of inducible nitric oxide synthase and nitric oxide production.

Animal Model:	APP/PS1 mice^[3]
Dosage:	5 mg/kg
Administration:	Orally gavage, daily for 6 months
Result:	Decreased levels of brain inflammatory markers. Ameliorated mitochondrial dysfunction. Reduced mitochondrial carbonyl protein. Enhanced SOD-2 expression. Reversed the phase 2 enzyme system. Had no effects on brain Aβ accumulation.

Animal Model:	Pristane-induced systemic lupus erythematous mice^[4]
Dosage:	0.4 mg
Administration:	Orally administration, daily for 6 months
Result:	Reduced paw swelling. Showed a slightly reduction of spleen and thymus.

Animal Model:	Diabetic rats^[6]
Dosage:	1, 5 and 10 mg/kg
Administration:	Orally administration, daily for 2 months
Result:	Reduced lipid peroxidation and nitrosative stress. Reduced prostaglandin E2 and interleukin 1ß. Reduced cell death.

Clinical Trial

Molecular Weight

154.16

Formula

C₈H₁₀O₃

CAS No.

10597-60-1

Appearance

Solid-Liquid Mixture

Color

Light yellow to yellow

SMILES

OC1=CC=C(CCO)C=C1O

Structure Classification

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (810.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 100 mg/mL (648.68 mM; Need ultrasonic)

Ethanol : 50 mg/mL (324.34 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	6.4868 mL	32.4338 mL	64.8677 mL
5 mM	1.2974 mL	6.4868 mL	12.9735 mL
10 mM	0.6487 mL	3.2434 mL	6.4868 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (13.49 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (13.49 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (13.49 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.60%

Select Batch:

Data Sheet (282 KB) SDS (393 KB)

COA (245 KB) HNMR (202 KB) LCMS (99 KB)

Handling Instructions (2659 KB)

References

[1]. Alblihed MA, et al. Hydroxytyrosol ameliorates oxidative challenge and inflammatory response associated with lipopolysaccharide-mediated sepsis in mice. Hum Exp Toxicol. 2021 Feb;40(2):342-354. [Content Brief]

[2]. Acín S, et al. Hydroxytyrosol administration enhances atherosclerotic lesion development in apo E deficient mice. J Biochem. 2006 Sep;140(3):383-91. [Content Brief]

[3]. Peng Y, et al. Hydroxytyrosol mildly improve cognitive function independent of APP processing in APP/PS1 mice. Mol Nutr Food Res. 2016 Nov;60(11):2331-2342. [Content Brief]

[4]. Marina Aparicio-Soto, et al. Dietary hydroxytyrosol and hydroxytyrosyl acetate supplementation prevent pristane-induced systemic lupus erythematous in mice, Journal of Functional Foods, Volume 29, 2017, Pages 84-92.

[5]. Masih Ghalandari, et al. Antimicrobial effect of Hydroxytyrosol, Hydroxytyrosol Acetate and Hydroxytyrosol Oleate on Staphylococcus Aureus and Staphylococcus Epidermidis. ELECTRON J GEN MED, Volume 15, Issue 4, August 2018, Article No: em46

[6]. Reyes JJ, et al. Neuroprotective Effect of Hydroxytyrosol in Experimental Diabetes Mellitus. J Agric Food Chem. 2017 Jun 7;65(22):4378-4383. [Content Brief]

[7]. Sun L, et al. Hydroxytyrosol induces apoptosis in human colon cancer cells through ROS generation. Food Funct. 2014 Aug;5(8):1909-14. [Content Brief]

[8]. Paolacci S, et al. In vitro and clinical studies on the efficacy of α-cyclodextrin and hydroxytyrosol against SARS-CoV-2 infection. Eur Rev Med Pharmacol Sci. 2021 Dec;25(1 Suppl):81-89. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol / H₂O / DMSO	1 mM	6.4868 mL	32.4338 mL	64.8677 mL	162.1692 mL
	5 mM	1.2974 mL	6.4868 mL	12.9735 mL	32.4338 mL
	10 mM	0.6487 mL	3.2434 mL	6.4868 mL	16.2169 mL
	15 mM	0.4325 mL	2.1623 mL	4.3245 mL	10.8113 mL
	20 mM	0.3243 mL	1.6217 mL	3.2434 mL	8.1085 mL
	25 mM	0.2595 mL	1.2974 mL	2.5947 mL	6.4868 mL
	30 mM	0.2162 mL	1.0811 mL	2.1623 mL	5.4056 mL
	40 mM	0.1622 mL	0.8108 mL	1.6217 mL	4.0542 mL
	50 mM	0.1297 mL	0.6487 mL	1.2974 mL	3.2434 mL
	60 mM	0.1081 mL	0.5406 mL	1.0811 mL	2.7028 mL
	80 mM	0.0811 mL	0.4054 mL	0.8108 mL	2.0271 mL
	100 mM	0.0649 mL	0.3243 mL	0.6487 mL	1.6217 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Hydroxytyrosol Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Hydroxytyrosol10597-60-1DOPET 3,4-Dihydroxyphenethyl alcohol 3-HydroxytyrosolApoptosisReactive Oxygen Species (ROS)BacterialSARS-CoVSARS coronavirusOlive oilROSColon cancerDiabetesAlzheimer's DiseaseAtherosclerosisInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Hydroxytyrosol (Synonyms: DOPET; 3,4-Dihydroxyphenethyl alcohol; 3-Hydroxytyrosol)

Customer Review

Other Forms of Hydroxytyrosol:

Hydroxytyrosol Related Antibodies

6 Publications Citing Use of MCE Hydroxytyrosol

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Hydroxytyrosol Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Hydroxytyrosol Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report